Incannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea
Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development
Incannex Healthcare Recognized for Innovative Drug Development Solutions by MedTech Breakthrough
Incannex Healthcare (NASDAQ:IXHL) and Cronos Group (NASDAQ:CRON) Financial Contrast
Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness
Incannex Reactivates Share Repurchase Program, Underscoring Confidence in Valuation and Strategic Position
Incannex Healthcare Announces Partnership with the AASM Foundation in Support of Sleep Apnea Research
Incannex Highlights Strong Balance Sheet with Approximately $75 Million in Cash and No Debt as Company Advances IHL-42X Development
Incannex Regains Compliance with Nasdaq Minimum Bid Price Requirement
Incannex Stock Slides As $10 Million Capital Raise Funds Next Study For Sleep Apnea Treatment
Incannex Healthcare Inc. Announces Pricing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Incannex Announces Reverse Stock Split
Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2026
Incannex Healthcare Announces Additional Appointments to Clinical Advisory Board
Incannex Healthcare Announces Formation of Clinical Advisory Board for PSX-001 Program
Incannex Healthcare Wins Research and Development Award for Obstructive Sleep Apnea Program in the 2025 Clinical Trials Arena Excellence Awards
Incannex Healthcare Delivers Transformational 2025 Progress and Outlines Well-Funded Outlook for 2026
Incannex Healthcare (NASDAQ:IXHL) Trading Down 8.8% – Here’s What Happened
Incannex Granted FDA Fast Track Designation for IHL-42X in Obstructive Sleep Apnea (OSA)
What Makes Incannex Healthcare Inc. (IXHL) a New Buy Stock
Incannex Healthcare (NASDAQ:IXHL) Trading Up 1.1% – Still a Buy?
Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 1Q 2026
Incannex Provides Shareholder Update Highlighting Clinical Progress, Capital Discipline, and EOY 2025 Strategic Focus
Incannex Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder
Incannex Healthcare Authorizes $20 Million Share Repurchase Program
Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 3Q 2025 - Update
Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea
Incannex Confirms Strong Cash Position; No Plans or Requirement to Fully Utilise ATM in Near Term
Incannex Reports Positive Topline Results from RePOSA Phase 2 Trial of IHL-42X
Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Charlene E. Gamaldo
Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Douglas B. Kirsch
Incannex achieves key milestone with database lock for RePOSA Phase 2 trial of IHL-42X
Incannex Healthcare Forms Joint Venture with Mind Medicine Australia to Expand Access to Psychedelic-Assisted Therapy
Incannex Healthcare Cancels All Outstanding Series A Warrants Following Strategic ATM Execution
Incannex Healthcare Inc. Expands IHL-42X Clinical Advisory Board with Appointments of Four Industry and Academic Leaders to Advance Obstructive Sleep Apnea (OSA) Program
Incannex Healthcare Inc. Advances IHL-42X RePOSA Trial to Phase 3 Following FDA Protocol Clearance
Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 3Q 2025
Incannex Healthcare Inc. Enters Agreement to Cancel Remaining Series A Warrants, Eliminating Up to 347.2 Million Shares from Potential Dilution Ahead of IHL-42X Phase 2 Topline Results
Incannex Healthcare Inc. Executes Strategic Cancellation of 50.4% of Series A Warrants, Significantly Reducing Potential Dilution
Incannex Announces Potential Reduction of Up to 50.4% of its Series A Warrants
Incannex Healthcare Inc. Reports Fiscal Third Quarter 2025 Financial Results and Business Updates
Incannex Healthcare (IXHL) Stock Soars Over 800%: What's Going On?
Incannex Healthcare Inc. Provides Clinical Program Update on IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)
Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)
Incannex Healthcare Inc. Announces Pricing of $12.5 Million Private Placement Priced at the Market Under Nasdaq Rules
Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2025
Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates
Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board
Incannex Healthcare Announces Positive Topline Results from Pharmacokinetics (PK) Study of IHL-42X, an Oral Combination Medicine for the Treatment of Obstructive Sleep Apnea